Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21,361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV.
Mateo R, Xu S, Shornikov A, Yazdi T, Liu Y, May L, Han B, Han D, Martin R, Manhas S, Richards C, Marceau C, Aeschbacher T, Chang S, Manuilov D, Hollnberger J, Urban S, Asselah T, Abdurakhmanov D, Lampertico P, Maiorova E, Mo H. Mateo R, et al. Among authors: chang s. JHEP Rep. 2023 Aug 22;5(11):100893. doi: 10.1016/j.jhepr.2023.100893. eCollection 2023 Nov. JHEP Rep. 2023. PMID: 37929228 Free PMC article.
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
Hollnberger J, Liu Y, Xu S, Chang S, Martin R, Manhas S, Aeschbacher T, Han B, Yazdi T, May L, Han D, Shornikov A, Flaherty J, Manuilov D, Suri V, Asselah T, Lampertico P, Wedemeyer H, Aleman S, Richards C, Mateo R, Maiorova E, Cihlar T, Mo H, Urban S. Hollnberger J, et al. Among authors: chang s. J Hepatol. 2023 Sep;79(3):657-665. doi: 10.1016/j.jhep.2023.04.027. Epub 2023 Apr 27. J Hepatol. 2023. PMID: 37120031 Clinical Trial.
Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification.
Hedskog C, Parhy B, Chang S, Zeuzem S, Moreno C, Shafran SD, Borgia SM, Asselah T, Alric L, Abergel A, Chen JJ, Collier J, Kapoor D, Hyland RH, Simmonds P, Mo H, Svarovskaia ES. Hedskog C, et al. Among authors: chang s. Open Forum Infect Dis. 2019 Feb 22;6(3):ofz076. doi: 10.1093/ofid/ofz076. eCollection 2019 Mar. Open Forum Infect Dis. 2019. PMID: 30949527 Free PMC article.
Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells.
Aggarwal A, Odorizzi PM, Brodbeck J, van Buuren N, Moon C, Chang S, Adona M, Suthram S, Suri V, Trowe T, Turner S, Marcellin P, Buti M, Gaggar A, Fletcher SP, Diehl L, Feierbach B, Balsitis S. Aggarwal A, et al. Among authors: chang s. JHEP Rep. 2022 Dec 26;5(4):100664. doi: 10.1016/j.jhepr.2022.100664. eCollection 2023 Apr. JHEP Rep. 2022. PMID: 36908748 Free PMC article.
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
D'Antoni ML, Andreatta K, Acosta R, Martin H, Chang S, Martin R, White KL. D'Antoni ML, et al. Among authors: chang s. J Acquir Immune Defic Syndr. 2022 Apr 1;89(4):433-440. doi: 10.1097/QAI.0000000000002888. J Acquir Immune Defic Syndr. 2022. PMID: 34897227 Free PMC article. Clinical Trial.
21,361 results
You have reached the last available page of results. Please see the User Guide for more information.